Inhaled antibiotic therapy for ventilator-associated tracheobronchitis and ventilator-associated pneumonia

An update

Tareq Abu-Salah, Rajiv Dhand

Research output: Contribution to journalReview article

31 Citations (Scopus)

Abstract

Ventilator-associated pneumonia (VAP) remains a leading cause of morbidity and mortality in mechanically-ventilated patients in the Intensive Care Unit (ICU). Ventilator-associated tracheobronchitis (VAT) was previously believed to be an intermediate stage between colonization of the lower respiratory tract and VAP. More recent data, however, suggest that VAT may be a separate entity that increases morbidity and mortality, independently of the occurrence of VAP. Some, but not all, patients with VAT progress to develop VAP. Although inhaled antibiotics alone could be effective for the treatment of VAP, the current consensus of opinion favors their role as adjuncts to systemic antimicrobial therapy for VAP. Inhaled antibiotics are increasingly employed for salvage therapy in patients with VAP due to multi-drug resistant Gram-negative bacteria. In contrast to VAP, VAT could be effectively treated with inhaled antibiotic therapy alone or in combination with systemic antimicrobials.

Original languageEnglish (US)
Pages (from-to)728-747
Number of pages20
JournalAdvances in Therapy
Volume28
Issue number9
DOIs
StatePublished - Sep 1 2011
Externally publishedYes

Fingerprint

Ventilator-Associated Pneumonia
Mechanical Ventilators
Anti-Bacterial Agents
Therapeutics
Morbidity
Salvage Therapy
Mortality
Gram-Negative Bacteria
Respiratory System
Intensive Care Units

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Inhaled antibiotic therapy for ventilator-associated tracheobronchitis and ventilator-associated pneumonia : An update. / Abu-Salah, Tareq; Dhand, Rajiv.

In: Advances in Therapy, Vol. 28, No. 9, 01.09.2011, p. 728-747.

Research output: Contribution to journalReview article

@article{070ca120fafc45e4bfea7df7ad5008e1,
title = "Inhaled antibiotic therapy for ventilator-associated tracheobronchitis and ventilator-associated pneumonia: An update",
abstract = "Ventilator-associated pneumonia (VAP) remains a leading cause of morbidity and mortality in mechanically-ventilated patients in the Intensive Care Unit (ICU). Ventilator-associated tracheobronchitis (VAT) was previously believed to be an intermediate stage between colonization of the lower respiratory tract and VAP. More recent data, however, suggest that VAT may be a separate entity that increases morbidity and mortality, independently of the occurrence of VAP. Some, but not all, patients with VAT progress to develop VAP. Although inhaled antibiotics alone could be effective for the treatment of VAP, the current consensus of opinion favors their role as adjuncts to systemic antimicrobial therapy for VAP. Inhaled antibiotics are increasingly employed for salvage therapy in patients with VAP due to multi-drug resistant Gram-negative bacteria. In contrast to VAP, VAT could be effectively treated with inhaled antibiotic therapy alone or in combination with systemic antimicrobials.",
author = "Tareq Abu-Salah and Rajiv Dhand",
year = "2011",
month = "9",
day = "1",
doi = "10.1007/s12325-011-0051-z",
language = "English (US)",
volume = "28",
pages = "728--747",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Health Communications Inc.",
number = "9",

}

TY - JOUR

T1 - Inhaled antibiotic therapy for ventilator-associated tracheobronchitis and ventilator-associated pneumonia

T2 - An update

AU - Abu-Salah, Tareq

AU - Dhand, Rajiv

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Ventilator-associated pneumonia (VAP) remains a leading cause of morbidity and mortality in mechanically-ventilated patients in the Intensive Care Unit (ICU). Ventilator-associated tracheobronchitis (VAT) was previously believed to be an intermediate stage between colonization of the lower respiratory tract and VAP. More recent data, however, suggest that VAT may be a separate entity that increases morbidity and mortality, independently of the occurrence of VAP. Some, but not all, patients with VAT progress to develop VAP. Although inhaled antibiotics alone could be effective for the treatment of VAP, the current consensus of opinion favors their role as adjuncts to systemic antimicrobial therapy for VAP. Inhaled antibiotics are increasingly employed for salvage therapy in patients with VAP due to multi-drug resistant Gram-negative bacteria. In contrast to VAP, VAT could be effectively treated with inhaled antibiotic therapy alone or in combination with systemic antimicrobials.

AB - Ventilator-associated pneumonia (VAP) remains a leading cause of morbidity and mortality in mechanically-ventilated patients in the Intensive Care Unit (ICU). Ventilator-associated tracheobronchitis (VAT) was previously believed to be an intermediate stage between colonization of the lower respiratory tract and VAP. More recent data, however, suggest that VAT may be a separate entity that increases morbidity and mortality, independently of the occurrence of VAP. Some, but not all, patients with VAT progress to develop VAP. Although inhaled antibiotics alone could be effective for the treatment of VAP, the current consensus of opinion favors their role as adjuncts to systemic antimicrobial therapy for VAP. Inhaled antibiotics are increasingly employed for salvage therapy in patients with VAP due to multi-drug resistant Gram-negative bacteria. In contrast to VAP, VAT could be effectively treated with inhaled antibiotic therapy alone or in combination with systemic antimicrobials.

UR - http://www.scopus.com/inward/record.url?scp=82455199209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82455199209&partnerID=8YFLogxK

U2 - 10.1007/s12325-011-0051-z

DO - 10.1007/s12325-011-0051-z

M3 - Review article

VL - 28

SP - 728

EP - 747

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 9

ER -